Ks logo

News & Insights

Subscribe
Icon search Icon close

  • People
  • OfficesIcon submenu
    • Icon submenu back back
    • Offices
    • North AmericaIcon submenu
      • Icon submenu back back
      • North America
      • Atlanta
      • Austin
      • Charlotte
      • Chicago
      • Denver
      • Houston
      • Los Angeles
      • Miami
      • New York
      • Northern Virginia
      • San Francisco
      • Silicon Valley
      • Washington, D.C.
    • Europe & Middle EastIcon submenu
      • Icon submenu back back
      • Europe & Middle East
      • Abu Dhabi
      • Brussels
      • Dubai
      • Frankfurt
      • Geneva
      • London
      • Paris
      • Riyadh
    • AsiaIcon submenu
      • Icon submenu back back
      • Asia
      • Singapore
      • Tokyo
  • CapabilitiesIcon submenu
    • Icon submenu back back
    • Capabilities
    • Corporate, Finance and InvestmentsIcon submenu
      • Icon submenu back back
      • Corporate, Finance and Investments
      • Overview
      • Activist Defense
      • Banking and Institutional Finance
      • Capital Markets
      • Construction and Procurement
      • Corporate Governance
      • Emerging Companies and Venture Capital
      • Employee Benefits and Executive Compensation
      • Energy and Infrastructure Projects
      • Financial Restructuring
      • Global Human Capital and Compliance
      • Investment Funds and Asset Management
      • Mergers and Acquisitions (M&A)
      • Middle East and Islamic Finance and Investment
      • Private Credit & Special Situations
      • Private Equity
      • Public Companies
      • Real Estate
      • Structured Finance and Securitization
      • Tax
      • Technology Transactions
    • Government MattersIcon submenu
      • Icon submenu back back
      • Government Matters
      • Overview
      • Antitrust
      • Data, Privacy and Security
      • Environmental, Health and Safety
      • FDA and Life Sciences
      • Government Advocacy and Public Policy
      • Government Contracts
      • Healthcare
      • International Trade
      • National Security and Corporate Espionage
      • Securities Enforcement and Regulation
      • Special Matters and Government Investigations
    • Trial and Global DisputesIcon submenu
      • Icon submenu back back
      • Trial and Global Disputes
      • Overview
      • Appellate, Constitutional and Administrative Law
      • Bankruptcy and Insolvency Litigation
      • Class Action Defense
      • Commercial Litigation
      • Construction and Engineering Disputes
      • Corporate and Securities Litigation
      • E-Discovery
      • Intellectual Property
      • International Arbitration and Litigation
      • Labor and Employment
      • Product Liability
      • Professional Liability
      • Toxic & Environmental Torts
    • Industries / IssuesIcon submenu
      • Icon submenu back back
      • Industries / Issues
      • Industries
      • Automotive, Transportation and Mobility
      • Energy
      • Financial Services
      • Food and Beverage
      • Higher Education
      • Life Sciences and Healthcare
      • Technology
      • Issues
      • #MeToo
      • Buy American
      • COVID-19 Vaccine Rollout
      • Crisis Management
      • Environmental Agenda
      • Environmental, Social and Governance (ESG)
      • Focus on Women's Health
      • Russia/Ukraine
      • Special Purpose Acquisition Companies (SPACs)
  • CareersIcon submenu
    • Icon submenu back back
    • Careers
    • LawyersIcon submenu
      • Icon submenu back back
      • Lawyers
      • Experienced Lawyers
    • StudentsIcon submenu
      • Icon submenu back back
      • Students
      • Law Students
      • UK Graduate Recruitment
    • Judicial ClerksIcon submenu
      • Icon submenu back back
      • Judicial Clerks
      • Judicial Clerks
    • Other ProfessionalsIcon submenu
      • Icon submenu back back
      • Other Professionals
      • Other Professionals
  • News & InsightsIcon submenu
    • Icon submenu back back
    • News & Insights
    • NewsIcon submenu
      • Icon submenu back back
      • News
      • Cases & Deals
      • In the News
      • Press Releases
      • Recognitions
    • EventsIcon submenu
      • Icon submenu back back
      • Events
      • Conferences
      • Speaking Engagements
      • Webinars
    • InsightsIcon submenu
      • Icon submenu back back
      • Insights
      • Newsletters
      • Client Alerts
      • Thought Leadership
      • Articles
      • Feature
      • BLOGS
      • COVID-19 Vaccine Updates
      • ESG Excellence
      • Energy Law Exchange
  • AboutIcon submenu
    • Icon submenu back back
    • About
    • Our FirmIcon submenu
      • Icon submenu back back
      • Our Firm
      • History
      • Our Values
    • Diversity & InclusionIcon submenu
      • Icon submenu back back
      • Diversity & Inclusion
      • Overview
      • Women’s Initiatives
      • Racial Diversity
      • LBGTQ+ Affinity
    • CitizenshipIcon submenu
      • Icon submenu back back
      • Citizenship
      • Overview
      • Pro Bono
      • Community Focus
  • Languages

News & Insights

  • NewsIcon submenu
    • Icon submenu back back
    • News
    • Cases & Deals
    • In the News
    • Press Releases
    • Recognitions
  • EventsIcon submenu
    • Icon submenu back back
    • Events
    • Conferences
    • Speaking Engagements
    • Webinars
  • InsightsIcon submenu
    • Icon submenu back back
    • Insights
    • Newsletters
    • Client Alerts
    • Thought Leadership
    • Articles
    • Feature
    • BLOGS
    • COVID-19 Vaccine Updates
    • ESG Excellence
    • Energy Law Exchange
< Back to Bio
Icon close orange Seth H. Lundy

Insights 39 results

Client Alert

April 25, 2022
COVID-19 Health Care Fraud Enforcement on the Rise: What’s Ahead for the Life Sciences & Healthcare Industries

Client Alert

March 28, 2022
AdvaMed Updates Code of Ethics on Interactions with HCPs: What’s the Impact on MedTech?

Article · Source: Chambers and Partners

March 21, 2022
Chambers Global Practice Guide: Pharmaceutical Advertising 2022

Client Alert

August 17, 2021
Revised PhRMA Code Provides Stricter Controls on HCP Speaker Programs

Article · Source: Chambers and Partners

March 19, 2021
Pharmaceutical Advertising

Article

March 11, 2021
Biden Administration - What's Ahead for the Life Sciences Industry?

Client Alert

February 3, 2021
Implementation of Final Rule Excluding PBM Rebates from Discount Safe Harbor Delayed Until 2023

Feature

January 15, 2021
General Counsel Internal Investigations Decision Tree for the Life Sciences Industry

Client Alert

December 17, 2020
CMS Proposes New DMEPOS Coverage Policies and Payment Rates, and Seeks to Codify HCPCS Application, Benefit Category and Payment Determination Processes

Client Alert

November 25, 2020
HHS Finalizes Rule Challenging Drug Manufacturer Rebates to PBMs and Payors

Client Alert

November 24, 2020
Are Pharma Speaker Programs Facing an Existential Crisis?

Client Alert

August 24, 2020
France – Thresholds for Prior Authorization of Agreements with Healthcare Professionals and for Benefits of Low Value are Finally Out

© 2022 King & Spalding LLP
  • Contact Us
  • Disclaimer
  • Privacy Notice
  • Transparency Disclosure
  • Cookie Policy
  • Copyright Notice
  • Regulatory Notices
  • K&S Alumni Group